Mucin-type O-glycosylation and its potential use in drug and vaccine development

Biochimica et Biophysica Acta - General Subjects

Volumn 1780, Issue 3, 2008, Pages 546-563

  Tarp, Mads Agervig ^a   Clausen, Henrik ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer vaccines; GalNAc transferases; Glycosyltransferases; Mucin type O glycosylation; Mucins; Site directed O glycosylation

Indexed keywords

CANCER VACCINE; DNA VACCINE; GLYCOPEPTIDE; HYBRID PROTEIN; MACROGOL; MUCIN; MUCIN 1; MUCIN O GLYCAN; N ACETYLGALACTOSAMINYLTRANSFERASE; POLYPEPTIDE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; NONHUMAN; OVARY ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; SERODIAGNOSIS; TRANSGENIC ANIMAL;

ANIMALS; CANCER VACCINES; DRUG DESIGN; GLYCOSYLATION; HUMANS; MUCINS; N-ACETYLGALACTOSAMINYLTRANSFERASES;

ANIMALIA;

EID: 40749160803     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2007.09.010     Document Type: Article

References (200)

1. Ellgaard L., and Helenius A. ER quality control: towards an understanding at the molecular level. Curr. Opin. Cell Biol. 13 (2001) 431-437
2. Helenius A., and Aebi M. Intracellular functions of N-linked glycans. Science 291 (2001) 2364-2369
3. Jentoft N. Why are proteins O-glycosylated?. Trends Biochem. Sci. 15 (1990) 291-294
4. Varki A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 3 (1993) 97-130
5. Amerongen A.V., Bolscher J.G., and Veerman E.C. Salivary mucins: protective functions in relation to their diversity. Glycobiology 5 (1995) 733-740
6. Paulson J.C. Glycoproteins: what are the sugar chains for?. Trends Biochem. Sci. 14 (1989) 272-276
7. McEver R.P. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells 16 (1990) 73-80
8. Taylor-Papadimitriou J., and Epenetos A.A. Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy. Trends Biotechnol. 12 (1994) 227-233
9. Kim Y.J., and Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj. J. 14 (1997) 569-576
10. Haltiwanger R.S., and Lowe J.B. Role of glycosylation in development. Ann. Rev. Biochem. 73 (2004) 491-537
11. Clausen H., and Bennett E.P. A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases control the initiation of mucin-type O-linked glycosylation. Glycobiology 6 (1996) 635-646
12. Hassan H., Bennet E.P., Mandel U., Hollingsworth M.A., and Clausen H. O-Glycan Occupancy is Directed by Substrate Specificities of Polypeptide GalNAc-Transferases. In: Ernst, Hart, and Sinay (Eds). Wiley-VCH chapter "Carbohydrates in Chemistry and Biology - a Comprehension Handbook" (2000) 273-292
13. Ten Hagen K.G., Fritz T.A., and Tabak L.A. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 13 (2003) 1R-16R
14. Ju T., Brewer K., D'Souza A., Cummings R.D., and Canfield W.M. Cloning and expression of human core 1 beta1,3-galactosyltransferase. J. Biol. Chem. 277 (2002) 178-186
15. Ju T., and Cummings R.D. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 437 (2005) 1252
16. Springer G.F. Tn epitope (N-acetyl-d-galactosamine alpha-O-serine/threonine) density in primary breast carcinoma: a functional predictor of aggressiveness. Mol. Immunol. 26 (1989) 1-5
17. Schietinger A., Philip M., Yoshida B.A., Azadi P., Liu H., Meredith S.C., and Schreiber H. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 314 (2006) 304-308
18. Bierhuizen M.F., and Fukuda M. Expression cloning of a cDNA encoding UDP-GlcNAc:Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 9326-9330
19. Schwientek T., Nomoto M., Levery S.B., Merkx G., van Kessel A.G., Bennett E.P., Hollingsworth M.A., and Clausen H. Control of O-glycan branch formation. Molecular cloning of human cDNA encoding a novel beta1, 6-N-acetylglucosaminyltransferase forming core 2 and core 4. J. Biol. Chem. 274 (1999) 4504-4512
20. Yeh J.C., Ong E., and Fukuda M. Molecular cloning and expression of a novel beta-1, 6-N-acetylglucosaminyltransferase that forms core 2, core 4, and I branches. J. Biol. Chem. 274 (1999) 3215-3221
21. Schwientek T., Yeh J.C., Levery S.B., Keck B., Merkx G., van Kessel A.G., Fukuda M., and Clausen H. Control of O-glycan branch formation. Molecular cloning and characterization of a novel thymus-associated core 2 beta1, 6-n-acetylglucosaminyltransferase. J. Biol. Chem. 275 (2000) 11106-11113
22. Ujita M., McAuliffe J., Schwientek T., Almeida R., Hindsgaul O., Clausen H., and Fukuda M. Synthesis of poly-N-acetyllactosamine in core 2 branched O-glycans. The requirement of novel beta-1,4-galactosyltransferase IV and beta-1,3-n-acetylglucosaminyltransferase. J. Biol. Chem. 273 (1998) 34843-34849
23. Maemura K., and Fukuda M. Poly-N-acetyllactosaminyl O-glycans attached to leukosialin. The presence of sialyl Le(x) structures in O-glycans. J. Biol. Chem. 267 (1992) 24379-24386
24. Yang J.M., Byrd J.C., Siddiki B.B., Chung Y.S., Okuno M., Sowa M., Kim Y.S., Matta K.L., and Brockhausen I. Alterations of O-glycan biosynthesis in human colon cancer tissues. Glycobiology 4 (1994) 873-884
25. Iwai T., Inaba N., Naundorf A., Zhang Y., Gotoh M., Iwasaki H., Kudo T., Togayachi A., Ishizuka Y., Nakanishi H., and Narimatsu H. Molecular cloning and characterization of a novel UDP-GlcNAc:GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase (beta 3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans. J. Biol. Chem. 277 (2002) 12802-12809
26. Kingsley P.D., Hagen K.G., Maltby K.M., Zara J., and Tabak L.A. Diverse spatial expression patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferase family member mRNAs during mouse development. Glycobiology 10 (2000) 1317-1323
27. Marth J.D. Complexity in O-linked oligosaccharide biosynthesis engendered by multiple polypeptide N-acetylgalactosaminyltransferases. Glycobiology 6 (1996) 701-705
28. Hazes B. The (QxW)3 domain: a flexible lectin scaffold. Protein Sci. 5 (1996) 1490-1501
29. Imberty A., Piller V., Piller F., and Breton C. Fold recognition and molecular modeling of a lectin-like domain in UDP-GalNac:polypeptide N-acetylgalactosaminyltransferases. Protein Eng. 10 (1997) 1353-1356
30. Gaskell A., Crennell S., and Taylor G. The three domains of a bacterial sialidase: a beta-propeller, an immunoglobulin module and a galactose-binding jelly-roll. Structure 3 (1995) 1197-1205
31. Buschiazzo A., Tavares G.A., Campetella O., Spinelli S., Cremona M.L., Paris G., Amaya M.F., Frasch A.C., and Alzari P.M. Structural basis of sialyltransferase activity in trypanosomal sialidases. EMBO J. 19 (2000) 16-24
32. Thobhani S., Ember B., Siriwardena A., and Boons G.J. Multivalency and the mode of action of bacterial sialidases. J. Am. Chem. Soc. 125 (2003) 7154-7155
33. Hassan H., Reis C.A., Bennett E.P., Mirgorodskaya E., Roepstorff P., Hollingsworth M.A., Burchell J., Taylor-Papadimitriou J., and Clausen H. The lectin domain of UDP-N-acetyl-d-galactosamine: polypeptide N-acetylgalactosaminyltransferase-T4 directs its glycopeptide specificities. J. Biol. Chem. 275 (2000) 38197-38205
34. Bennett E.P., Hassan H., Hollingsworth M.A., and Clausen H. A novel human UDP-N-acetyl-d-galactosamine:polypeptide N-acetylgalactosaminyltransferase, GalNAc-T7, with specificity for partial GalNAc-glycosylated acceptor substrates. FEBS Lett. 460 (1999) 226-230
35. Ten Hagen K.G., Bedi G.S., Tetaert D., Kingsley P.D., Hagen F.K., Balys M.M., Beres T.M., Degand P., and Tabak L.A. Cloning and characterization of a ninth member of the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family, ppGaNTase-T9. J. Biol. Chem. 276 (2001) 17395-17404
36. Fritz T.A., Hurley J.H., Trinh L.B., Shiloach J., and Tabak L.A. The beginnings of mucin biosynthesis: the crystal structure of UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase-T1. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 15307-15312
37. Fritz T.A., Raman J., and Tabak L.A. Dynamic association between the catalytic and lectin domains of human UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase-2. J. Biol. Chem. 281 (2006) 8613-8619
38. Kubota T., Shiba T., Sugioka S., Furukawa S., Sawaki H., Kato R., Wakatsuki S., and Narimatsu H. Structural basis of carbohydrate transfer activity by human UDP-GalNAc: polypeptide alpha-N-acetylgalactosaminyltransferase (pp-GalNAc-T10). J. Mol. Biol. 359 (2006) 708-727
39. Wandall H.H., Irazoqui F., Tarp M.A., Bennett E.P., Mandel U., Takeuchi H., Kato K., Irimura T., Suryanarayanan G., Hollingsworth M.A., and Clausen H. The lectin domains of polypeptide GalNAc-transferases exhibit carbohydrate-binding specificity for GalNAc: lectin binding to GalNAc-glycopeptide substrates is required for high density GalNAc-O-glycosylation. Glycobiology 17 (2007) 374-387
40. Wilson I.B., Gavel Y., and von H.G. Amino acid distributions around O-linked glycosylation sites. Biochem. J. 275 Pt 2 (1991) 529-534
41. O'Connell B., Tabak L.A., and Ramasubbu N. The influence of flanking sequences on O-glycosylation. Biochem. Biophys. Res. Commun. 180 (1991) 1024-1030
42. Hansen J.E., Lund O., Engelbrecht J., Bohr H., Nielsen J.O., and Hansen J.E. Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. Biochem. J. 308 Pt 3 (1995) 801-813
43. Hansen J.E., Lund O., Tolstrup N., Gooley A.A., Williams K.L., and Brunak S. NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconj. J. 15 (1998) 115-130
44. Thanka Christlet T.H., and Veluraja K. Database analysis of O-glycosylation sites in proteins. Biophys. J. 80 (2001) 952-960
45. Julenius K., Molgaard A., Gupta R., and Brunak S. Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology 15 (2005) 153-164
46. O'Connell B.C., Hagen F.K., and Tabak L.A. The influence of flanking sequence on the O-glycosylation of threonine in vitro. J. Biol. Chem. 267 (1992) 25010-25018
47. O'Connell B.C., and Tabak L.A. A comparison of serine and threonine O-glycosylation by UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. J. Dent. Res. 72 (1993) 1554-1558
48. Nishimori I., Johnson N.R., Sanderson S.D., Perini F., Mountjoy K., Cerny R.L., Gross M.L., and Hollingsworth M.A. Influence of acceptor substrate primary amino acid sequence on the activity of human UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase. Studies with the MUC1 tandem repeat. J. Biol. Chem. 269 (1994) 16123-16130
49. Nishimori I., Perini F., Mountjoy K.P., Sanderson S.D., Johnson N., Cerny R.L., Gross M.L., Fontenot J.D., and Hollingsworth M.A. N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts. Cancer Res. 54 (1994) 3738-3744
50. Stadie T.R., Chai W., Lawson A.M., Byfield P.G., and Hanisch F.G. Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells. Eur. J. Biochem. 229 (1995) 140-147
51. Clausen H., Pallesen T., White T., Wandall H., and Hansen S. In: Bock K., and Clausen H. (Eds). Complex Carbohydrates in Drug Research. Structural and Functional Aspects (1994), Munksgaard, Copenhagen 297-310
52. Wandall H.H., Hassan H., Mirgorodskaya E., Kristensen A.K., Roepstorff P., Bennett E.P., Nielsen P.A., Hollingsworth M.A., Burchell J., Taylor-Papadimitriou J., and Clausen H. Substrate specificities of three members of the human UDP-N-acetyl-alpha-d-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3. J. Biol. Chem. 272 (1997) 23503-23514
53. Bennett E.P., Hassan H., Mandel U., Hollingsworth M.A., Akisawa N., Ikematsu Y., Merkx G., van Kessel A.G., Olofsson S., and Clausen H. Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha-d-galactosamine:Polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6. Evidence for genetic but not functional redundancy. J. Biol. Chem. 274 (1999) 25362-25370
54. Bennett E.P., Hassan H., Mandel U., Mirgorodskaya E., Roepstorff P., Burchell J., Taylor-Papadimitriou J., Hollingsworth M.A., Merkx G., van Kessel A.G., Eiberg H., Steffensen R., and Clausen H. Cloning of a human UDP-N-acetyl-alpha-d-galactosamine:polypeptide N-acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat. J. Biol. Chem. 273 (1998) 30472-30481
55. Nehrke K., Hagen F.K., and Tabak L.A. Charge distribution of flanking amino acids influences O-glycan acquisition in vivo. J. Biol. Chem. 271 (1996) 7061-7065
56. Nehrke K., Ten Hagen K.G., Hagen F.K., and Tabak L.A. Charge distribution of flanking amino acids inhibits O-glycosylation of several single-site acceptors in vivo. Glycobiology 7 (1997) 1053-1060
57. Nehrke K., Hagen F.K., and Tabak L.A. Isoform-specific O-glycosylation by murine UDP-GalNAc:polypeptide N- acetylgalactosaminyltransferase-T3, in vivo. Glycobiology 8 (1998) 367-371
58. Bennett E.P., Hassan H., and Clausen H. cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-d-galactosamine: Polypeptide N-acetylgalactosaminyltransferase, GalNAc-t3. J. Biol. Chem. 271 (1996) 17006-17012
59. Gerken T.A., Zhang J., Levine J., and Elhammer A. Mucin core O-glycosylation is modulated by neighboring residue glycosylation status. Kinetic modeling of the site-specific glycosylation of the apo-porcine submaxillary mucin tandem repeat by UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases T1 and T2. J. Biol. Chem. 277 (2002) 49850-49862
60. Gerken T.A., Tep C., and Rarick J. Role of peptide sequence and neighboring residue glycosylation on the substrate specificity of the uridine 5′-diphosphate-alpha-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyl transferases T1 and T2: kinetic modeling of the porcine and canine submaxillary gland mucin tandem repeats. Biochemistry 43 (2004) 9888-9900
61. Gerken T.A., Raman J., Fritz T.A., and Jamison O. Identification of common and unique peptide substrate preferences for the UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferases T1 and T2 derived from oriented random peptide substrates. J. Biol. Chem. 281 (2006) 32403-32416
62. Mardberg K., Trybala E., Glorioso J.C., and Bergstrom T. Mutational analysis of the major heparan sulfate-binding domain of herpes simplex virus type 1 glycoprotein C. J. Gen. Virol. 82 (2001) 1941-1950
63. Mardberg K., Trybala E., Tufaro F., and Bergstrom T. Herpes simplex virus type 1 glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing gro2C cells. J. Gen. Virol. 83 (2002) 291-300
64. Mardberg K., Nystrom K., Tarp M.A., Trybala E., Clausen H., Bergstrom T., and Olofsson S. Basic amino acids as modulators of an O-linked glycosylation signal of the herpes simplex virus type 1 glycoprotein gC: functional roles in viral infectivity. Glycobiology 14 (2004) 571-581
65. McGeoch D.J., Dolan A., Donald S., and Rixon F.J. Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1. J. Mol. Biol. 181 (1985) 1-13
66. Norberg P., Olofsson S., Tarp M.A., Clausen H., Bergstrom T., and Liljeqvist J.A. Glycoprotein I of herpes simplex virus type 1 contains a unique polymorphic tandem-repeated mucin region. J. Gen. Virol. 88 (2007) 1683-1688
67. Topaz O., Bergman R., Mandel U., Maor G., Goldberg R., Richard G., and Sprecher E. Absence of intraepidermal glycosyltransferase ppGalNac-T3 expression in familial tumoral calcinosis. Am. J. Dermatopathol. 27 (2005) 211-215
68. Ichikawa S., Lyles K.W., and Econs M.J. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J. Clin. Endocrinol. Metab. 90 (2005) 2420-2423
69. Benet-Pages A., Orlik P., Strom T.M., and Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 14 (2005) 385-390
70. Larsson T., Davis S.I., Garringer H.J., Mooney S.D., Draman M.S., Cullen M.J., and White K.E. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146 (2005) 3883-3891
71. Araya K., Fukumoto S., Backenroth R., Takeuchi Y., Nakayama K., Ito N., Yoshii N., Yamazaki Y., Yamashita T., Silver J., Igarashi T., and Fujita T. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J. Clin. Endocrinol. Metab. 90 (2005) 5523-5527
72. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., Takeuchi Y., Fujita T., Nakahara K., Yamashita T., and Fukumoto S. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87 (2002) 4957-4960
73. Kato K., Jeanneau C., Tarp M.A., Benet-Pages A., Lorenz-Depiereux B., Bennett E.P., Mandel U., Strom T.M., and Clausen H. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J. Biol. Chem. 281 (2006) 18370-18377
74. Hennet T., Hagen F.K., Tabak L.A., and Marth J.D. T-cell-specific deletion of a polypeptide N-acetylgalactosaminyl-transferase gene by site-directed recombination. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 12070-12074
75. Manzi A.E., Norgard-Sumnicht K., Argade S., Marth J.D., van H.H., and Varki A. Exploring the glycan repertoire of genetically modified mice by isolation and profiling of the major glycan classes and nano-NMR analysis of glycan mixtures. Glycobiology 10 (2000) 669-689
76. Zhang Y., Iwasaki H., Wang H., Kudo T., Kalka T.B., Hennet T., Kubota T., Cheng L., Inaba N., Gotoh M., Togayachi A., Guo J., Hisatomi H., Nakajima K., Nishihara S., Nakamura M., Marth J.D., and Narimatsu H. Cloning and characterization of a new human UDP-N-acetyl-alpha-d-galactosamine:polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen. J. Biol. Chem. 278 (2003) 573-584
77. Schwientek T., Bennett E.P., Flores C., Thacker J., Hollmann M., Reis C.A., Behrens J., Mandel U., Keck B., Schafer M.A., Haselmann K., Zubarev R., Roepstorff P., Burchell J.M., Taylor-Papadimitriou J., Hollingsworth M.A., and Clausen H. Functional conservation of subfamilies of putative UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans, and mammals. One subfamily composed of l(2)35Aa is essential in Drosophila. J. Biol. Chem. 277 (2002) 22623-22638
78. Ten Hagen K.G., and Tran D.T. A UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase is essential for viability in Drosophila melanogaster. J. Biol. Chem. 277 (2002) 22616-22622
79. Defrees S., Wang Z.G., Xing R., Scott A.E., Wang J., Zopf D., Gouty D.L., Sjoberg E.R., Panneerselvam K., Brinkman-Van der Linden E.C., Bayer R.J., Tarp M.A., and Clausen H. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16 (2006) 833-843
80. Kubota N., Orita T., Hattori K., Oh-eda M., Ochi N., and Yamazaki T. Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J. Biochem.(Tokyo) 107 (1990) 486-492
81. Adolf G.R., Kalsner I., Ahorn H., Maurer-Fogy I., and Cantell K. Natural human interferon-alpha 2 is O-glycosylated. Biochem. J. 276 Pt 2 (1991) 511-518
82. Kaushansky K., O'Hara P.J., Hart C.E., Forstrom J.W., and Hagen F.S. Role of carbohydrate in the function of human granulocyte-macrophage colony-stimulating factor. Biochemistry 26 (1987) 4861-4867
83. Backstrom M., Link T., Olson F.J., Karlsson H., Graham R., Picco G., Burchell J., Taylor-Papadimitriou J., Noll T., and Hansson G.C. Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells. Biochem. J. 376 (2003) 677-686
84. Hollingsworth M.A., and Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat. Rev., Cancer 4 (2004) 45-60
85. Baldus S.E., Engelmann K., and Hanisch F.G. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit. Rev. Clin. Lab. Sci. 41 (2004) 189-231
86. Gendler S.J., and Spicer A.P. Epithelial mucin genes. Annu. Rev. Physiol. 57 (1995) 607-634
87. Springer T.A. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu. Rev. Physiol. 57 (1995) 827-872
88. McEver R.P. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj. J. 14 (1997) 585-591
89. Taylor-Papadimitriou J., Peterson J.A., Arklie J., Burchell J., Ceriani R.L., and Bodmer W.F. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int. J. Cancer 28 (1981) 17-21
90. Gendler S.J., Lancaster C.A., Taylor-Papadimitriou J., Duhig T., Peat N., Burchell J., Pemberton L., Lalani E.N., and Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 265 (1990) 15286-15293
91. Lan M.S., Batra S.K., Qi W.N., Metzgar R.S., and Hollingsworth M.A. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J. Biol. Chem. 265 (1990) 15294-15299
92. Ligtenberg M.J., Vos H.L., Gennissen A.M., and Hilkens J. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J. Biol. Chem. 265 (1990) 5573-5578
93. Agrawal B., Krantz M.J., Parker J., and Longenecker B.M. Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res. 58 (1998) 4079-4081
94. Wykes M., MacDonald K.P., Tran M., Quin R.J., Xing P.X., Gendler S.J., Hart D.N., and McGuckin M.A. MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. J. Leukoc. Biol. 72 (2002) 692-701
95. Burchell J.M., Mungul A., and Taylor-Papadimitriou J. O-linked glycosylation in the mammary gland: changes that occur during malignancy. J. Mammary Gland Biol. Neoplasia 6 (2001) 355-364
96. Kufe D., Inghirami G., Abe M., Hayes D., Justi-Wheeler H., and Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3 (1984) 223-232
97. Taylor-Papadimitriou J., Burchell J., Miles D.W., and Dalziel M. MUC1 and cancer. Biochim. Biophys. Acta 1455 (1999) 301-313
98. Rughetti A., Turchi V., Ghetti C.A., Scambia G., Panici P.B., Roncucci G., Mancuso S., Frati L., and Nuti M. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res. 53 (1993) 2457-2459
99. von Mensdorff-Pouilly S., Petrakou E., Kenemans P., van U.K., Verstraeten A.A., Snijdewint F.G., van Kamp G.J., Schol D.J., Reis C.A., Price M.R., Livingston P.O., and Hilgers J. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int. J. Cancer 86 (2000) 702-712
100. von Mensdorff-Pouilly S., Verstraeten A.A., Kenemans P., Snijdewint F.G., Kok A., van Kamp G.J., Paul M.A., Van Diest P.J., Meijer S., and Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. 18 (2000) 574-583
101. Samuel J., and Longenecker B.M. Development of active specific immunotherapeutic agents based on cancer-associated mucins. Pharm. Biotechnol. 6 (1995) 875-890
102. Apostolopoulos V., McKenzie I.F., and Pietersz G.A. Breast cancer immunotherapy: current status and future prospects. Immunol. Cell Biol. 74 (1996) 457-464
103. Springer G.F. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J. Mol. Med. 75 (1997) 594-602
104. Swallow D.M., Gendler S., Griffiths B., Kearney A., Povey S., Sheer D., Palmer R.W., and Taylor-Papadimitriou J. The hypervariable gene locus PUM, which codes for the tumour associated epithelial mucins, is located on chromosome 1, within the region 1q21-24. Ann. Hum. Genet. 51 (1987) 289-294
105. Ligtenberg M.J., Kruijshaar L., Buijs F., van M.M., Litvinov S.V., and Hilkens J. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J. Biol. Chem. 267 (1992) 6171-6177
106. Gendler S., Taylor-Papadimitriou J., Duhig T., Rothbard J., and Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol. Chem. 263 (1988) 12820-12823
107. Muller S., Alving K., Peter-Katalinic J., Zachara N., Gooley A.A., and Hanisch F.G. High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells. J. Biol. Chem. 274 (1999) 18165-18172
108. Zrihan-Licht S., Baruch A., Elroy-Stein O., Keydar I., and Wreschner D.H. Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. FEBS Lett. 356 (1994) 130-136
109. Wreschner D.H., McGuckin M.A., Williams S.J., Baruch A., Yoeli M., Ziv R., Okun L., Zaretsky J., Smorodinsky N., Keydar I., Neophytou P., Stacey M., Lin H.H., and Gordon S. Generation of ligand-receptor alliances by "SEA" module-mediated cleavage of membrane-associated mucin proteins. Protein Sci. 11 (2002) 698-706
110. Levitin F., Stern O., Weiss M., Gil-Henn C., Ziv R., Prokocimer Z., Smorodinsky N.I., Rubinstein D.B., and Wreschner D.H. The MUC1 SEA module is a self-cleaving domain. J. Biol. Chem. 280 (2005) 33374-33386
111. Macao B., Johansson D.G., Hansson G.C., and Hard T. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat. Struct. Mol. Biol. 13 (2006) 71-76
112. Springer G.F. T and Tn, general carcinoma autoantigens. Science 224 (1984) 1198-1206
113. Avichezer D., Springer G.F., Schechter B., and Arnon R. Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Int. J. Cancer 72 (1997) 119-127
114. Lloyd K.O., Burchell J., Kudryashov V., Yin B.W., and Taylor-Papadimitriou J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J. Biol. Chem. 271 (1996) 33325-33334
115. Dalziel M., Whitehouse C., McFarlane I., Brockhausen I., Gschmeissner S., Schwientek T., Clausen H., Burchell J.M., and Taylor-Papadimitriou J. The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J. Biol. Chem. 276 (2001) 11007-11015
116. Brockhausen I., Yang J.M., Burchell J., Whitehouse C., and Taylor-Papadimitriou J. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur. J. Biochem. 233 (1995) 607-617
117. Whitehouse C., Burchell J., Gschmeissner S., Brockhausen I., Lloyd K.O., and Taylor-Papadimitriou J. A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2-based O-glycans. J. Cell Biol. 137 (1997) 1229-1241
118. Yousefi S., Higgins E., Daoling Z., Pollex-Kruger A., Hindsgaul O., and Dennis J.W. Increased UDP-GlcNAc:Gal beta 1-3GaLNAc-R (GlcNAc to GaLNAc) beta-1, 6-N-acetylglucosaminyltransferase activity in metastatic murine tumor cell lines. Control of polylactosamine synthesis. J. Biol. Chem. 266 (1991) 1772-1782
119. Hagisawa S., Ohyama C., Takahashi T., Endoh M., Moriya T., Nakayama J., Arai Y., and Fukuda M. Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. Glycobiology 15 (2005) 1016-1024
120. Muller S., and Hanisch F.G. Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation. J. Biol. Chem. 277 (2002) 26103-26112
121. Muller S., Goletz S., Packer N., Gooley A., Lawson A.M., and Hanisch F.G. Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1. All putative sites within the tandem repeat are glycosylation targets in vivo. J. Biol. Chem. 272 (1997) 24780-24793
122. Hanisch F.G., Muller S., Hassan H., Clausen H., Zachara N., Gooley A.A., Paulsen H., Alving K., and Peter-Katalinic J. Dynamic epigenetic regulation of initial O-glycosylation by UDP-N-Acetylgalactosamine:Peptide N-acetylgalactosaminyltransferases. site-specific glycosylation of MUC1 repeat peptide influences the substrate qualities at adjacent or distant Ser/Thr positions. J. Biol. Chem. 274 (1999) 9946-9954
123. Vlad A.M., Muller S., Cudic M., Paulsen H., Otvos Jr. L., Hanisch F.G., and Finn O.J. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J. Exp. Med. 196 (2002) 1435-1446
124. Hanisch F.G., Schwientek T., Bergwelt-Baildon M.S., Schultze J.L., and Finn O. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur. J. Immunol. 33 (2003) 3242-3254
125. Hilkens J., Ligtenberg M.J., Vos H.L., and Litvinov S.V. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem. Sci. 17 (1992) 359-363
126. Ligtenberg M.J., Buijs F., Vos H.L., and Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res. 52 (1992) 2318-2324
127. Wesseling J., d. van V., Vos H.L., Sonnenberg A., and Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 129 (1995) 255-265
128. Wesseling J., d.van V., and Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell 7 (1996) 565-577
129. Kondo K., Kohno N., Yokoyama A., and Hiwada K. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res. 58 (1998) 2014-2019
130. Yamamoto M., Bharti A., Li Y., and Kufe D. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J. Biol. Chem. 272 (1997) 12492-12494
131. Li Y., Bharti A., Chen D., Gong J., and Kufe D. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol. Cell. Biol. 18 (1998) 7216-7224
132. Li Y., Kuwahara H., Ren J., Wen G., and Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J. Biol. Chem. 276 (2001) 6061-6064
133. Li Y., Ren J., Yu W., Li Q., Kuwahara H., Yin L., Carraway III K.L., and Kufe D. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J. Biol. Chem. 276 (2001) 35239-35242
134. Suwa T., Hinoda Y., Makiguchi Y., Takahashi T., Itoh F., Adachi M., Hareyama M., and Imai K. Increased invasiveness of MUC1 and cDNA-transfected human gastric cancer MKN74 cells. Int. J. Cancer 76 (1998) 377-382
135. Hudson M.J., Stamp G.W., Hollingsworth M.A., Pignatelli M., and Lalani E.N. MUC1 expressed in PanC1 cells decreases adhesion to type 1 collagen but increases contraction in collagen lattices. Am. J. Pathol. 148 (1996) 951-960
136. Satoh S., Hinoda Y., Hayashi T., Burdick M.D., Imai K., and Hollingsworth M.A. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int. J. Cancer 88 (2000) 507-518
137. Zhang K., Baeckstrom D., Brevinge H., and Hansson G.C. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. J. Cell. Biochem. 60 (1996) 538-549
138. Sikut R., Zhang K., Baeckstrom D., and Hansson G.C. Distinct sub-populations of carcinoma-associated MUC1 mucins as detected by the monoclonal antibody 9H8 and antibodies against the sialyl-Lewis a and sialyl-Lewis x epitopes in the circulation of breast-cancer patients. Int. J. Cancer 66 (1996) 617-623
139. Regimbald L.H., Pilarski L.M., Longenecker B.M., Reddish M.A., Zimmermann G., and Hugh J.C. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 56 (1996) 4244-4249
140. Rahn J.J., Chow J.W., Horne G.J., Mah B.K., Emerman J.T., Hoffman P., and Hugh J.C. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin. Exp. Metastasis 22 (2005) 475-483
141. Kam J.L., Regimbald L.H., Hilgers J.H., Hoffman P., Krantz M.J., Longenecker B.M., and Hugh J.C. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. Cancer Res. 58 (1998) 5577-5581
142. Hinoda Y., Nakagawa N., Nakamura H., Makiguchi Y., Itoh F., Adachi M., Yabana T., Imai K., and Yachi A. Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. Immunol. Lett. 35 (1993) 163-168
143. Kotera Y., Fontenot J.D., Pecher G., Metzgar R.S., and Finn O.J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 54 (1994) 2856-2860
144. Richards E.R., Devine P.L., Quin R.J., Fontenot J.D., Ward B.G., and McGuckin M.A. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol. Immunother. 46 (1998) 245-252
145. Gourevitch M.M., von Mensdorff-Pouilly S., Litvinov S.V., Kenemans P., van Kamp G.J., Verstraeten A.A., and Hilgers J. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br. J. Cancer 72 (1995) 934-938
146. Hamanaka Y., Suehiro Y., Fukui M., Shikichi K., Imai K., and Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int. J. Cancer 103 (2003) 97-100
147. Zhang K., Sikut R., and Hansson G.C. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol. 176 (1997) 158-165
148. Hayes D.F., Silberstein D.S., Rodrique S.W., and Kufe D.W. DF3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibody-coated targets. J. Immunol. 145 (1990) 962-970
149. van de Wiel-van Kemenade, Ligtenberg M.J., de Boer A.J., Buijs F., Vos H.L., Melief C.J., Hilkens J., and Figdor C.G. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 151 (1993) 767-776
150. Carlos C.A., Dong H.F., Howard O.M., Oppenheim J.J., Hanisch F.G., and Finn O.J. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J. Immunol. 175 (2005) 1628-1635
151. Rughetti A., Pellicciotta I., Biffoni M., Backstrom M., Link T., Bennet E.P., Clausen H., Noll T., Hansson G.C., Burchell J.M., Frati L., Taylor-Papadimitriou J., and Nuti M. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J. Immunol. 174 (2005) 7764-7772
152. Barnd D.L., Lan M.S., Metzgar R.S., and Finn O.J. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 7159-7163
153. Jerome K.R., Domenech N., and Finn O.J. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J. Immunol. 151 (1993) 1654-1662
154. Domenech N., Henderson R.A., and Finn O.J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol. 155 (1995) 4766-4774
155. Reddish M., MacLean G.D., Koganty R.R., Kan-Mitchell J., Jones V., Mitchell M.S., and Longenecker B.M. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int. J. Cancer 76 (1998) 817-823
156. Agrawal B., Krantz M.J., Reddish M.A., and Longenecker B.M. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int. Immunol. 10 (1998) 1907-1916
157. Apostolopoulos V., Yuriev E., Ramsland P.A., Halton J., Osinski C., Li W., Plebanski M., Paulsen H., and McKenzie I.F. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15029-15034
158. Galli-Stampino L., Meinjohanns E., Frische K., Meldal M., Jensen T., Werdelin O., and Mouritsen S. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res. 57 (1997) 3214-3222
159. Gad M., Jensen T., Gagne R., Komba S., Daugaard S., Kroman N., Meldal M., and Werdelin O. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue. Eur. J. Immunol. 33 (2003) 1624-1632
160. Napoletano C., Rughetti A., Tarp M.A., Coleman J., Bennett E.P., Picco G., Sale P., Denda-Nagai K., Irimura T., Mandel U., Clausen H., Frati L., Taylor-Papadimitriou J., Burchell J., and Nuti M. Tumor Associated Tn-MUC1 Glycoform is internalized through the Macrophage Galactose-type C-type Lectin and delivered to the HLA Class I and II Compartments in Dendritic Cells. Cancer Res. 67 (2007) 8358-8367
161. Agrawal B., Reddish M.A., Krantz M.J., and Longenecker B.M. Does pregnancy immunize against breast cancer?. Cancer Res. 55 (1995) 2257-2261
162. Ding L., Lalani E.N., Reddish M., Koganty R., Wong T., Samuel J., Yacyshyn M.B., Meikle A., Fung P.Y., and Taylor-Papadimitriou J. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 36 (1993) 9-17
163. Zhang S., Graeber L.A., Helling F., Ragupathi G., Adluri S., Lloyd K.O., and Livingston P.O. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res. 56 (1996) 3315-3319
164. Soares M.M., Mehta V., and Finn O.J. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166 (2001) 6555-6563
165. Goydos J.S., Elder E., Whiteside T.L., Finn O.J., and Lotze M.T. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63 (1996) 298-304
166. Ramanathan R.K., Lee K.M., McKolanis J., Hitbold E., Schraut W., Moser A.J., Warnick E., Whiteside T., Osborne J., Kim H., Day R., Troetschel M., and Finn O.J. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 54 (2005) 254-264
167. Adluri S., Gilewski T., Zhang S., Ramnath V., Ragupathi G., and Livingston P. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Br. J. Cancer 79 (1999) 1806-1812
168. Gilewski T., Adluri S., Ragupathi G., Zhang S., Yao T.J., Panageas K., Moynahan M., Houghton A., Norton L., and Livingston P.O. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6 (2000) 1693-1701
169. Palmer M., Parker J., Modi S., Butts C., Smylie M., Meikle A., Kehoe M., MacLean G., and Longenecker M. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer 3 (2001) 49-57
170. Apostolopoulos V., Pietersz G.A., Loveland B.E., Sandrin M.S., and McKenzie I.F. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 10128-10132
171. Lees C.J., Apostolopoulos V., Acres B., Ramshaw I., Ramsay A., Ong C.S., and McKenzie I.F. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine 19 (2000) 158-162
172. Karanikas V., Thynne G., Mitchell P., Ong C.S., Gunawardana D., Blum R., Pearson J., Lodding J., Pietersz G., Broadbent R., Tait B., and McKenzie I.F. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J. Immunother. 24 (2001) 172-183
173. Karanikas V., Hwang L.A., Pearson J., Ong C.S., Apostolopoulos V., Vaughan H., Xing P.X., Jamieson G., Pietersz G., Tait B., Broadbent R., Thynne G., and McKenzie I.F. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100 (1997) 2783-2792
174. Apostolopoulos V., Pietersz G.A., Tsibanis A., Tsikkinis A., Drakaki H., Loveland B.E., Piddlesden S.J., Plebanski M., Pouniotis D.S., Alexis M.N., McKenzie I.F., and Vassilaros S. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 8 (2006) R27
175. Graham R.A., Burchell J.M., Beverley P., and Taylor-Papadimitriou J. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int. J. Cancer 65 (1996) 664-670
176. Plunkett T., Graham R., Correa I., Sewell R., Miles D., Burchell J., and Taylor-Papadimitriou J. Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain. Int. J. Cancer 109 (2004) 691-697
177. Snyder L.A., Goletz T.J., Gunn G.R., Shi F.F., Harris M.C., Cochlin K., McCauley C., McCarthy S.G., Branigan P.J., and Knight D.M. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine 24 (2006) 3340-3352
178. Scholl S.M., Balloul J.M., Le G.G., Bizouarne N., Schatz C., Kieny M.P., von Mensdorff-Pouilly S., Vincent-Salomon A., Deneux L., Tartour E., Fridman W., Pouillart P., and Acres B. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. 23 (2000) 570-580
179. Liu M., Acres B., Balloul J.M., Bizouarne N., Paul S., Slos P., and Squiban P. Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. U. S. A. 101 Suppl 2 (2004) 14567-14571
180. Madan R.A., Arlen P.M., and Gulley J.L. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert. Opin. Biol. Ther. 7 (2007) 543-554
181. Trevor K.T., Hersh E.M., Brailey J., Balloul J.M., and Acres B. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol. Immunother. 50 (2001) 397-407
182. Van Leeuwen E.B., Cloosen S., Senden-Gijsbers B.L., Agervig T.M., Mandel U., Clausen H., Havenga M.J., Duffour M.T., Garcia-Vallejo J.J., Germeraad W.T., and Bos G.M. Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector. Cytotherapy 8 (2006) 24-35
183. Tanaka Y., Koido S., Chen D., Gendler S.J., Kufe D., and Gong J. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin. Immunol. 101 (2001) 192-200
184. Brossart P., Wirths S., Stuhler G., Reichardt V.L., Kanz L., and Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96 (2000) 3102-3108
185. Wierecky J., Muller M.R., Wirths S., Halder-Oehler E., Dorfel D., Schmidt S.M., Hantschel M., Brugger W., Schroder S., Horger M.S., Kanz L., and Brossart P. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66 (2006) 5910-5918
186. Loveland B.E., Zhao A., White S., Gan H., Hamilton K., Xing P.X., Pietersz G.A., Apostolopoulos V., Vaughan H., Karanikas V., Kyriakou P., McKenzie I.F., and Mitchell P.L. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 12 (2006) 869-877
187. O'Boyle K.P., Zamore R., Adluri S., Cohen A., Kemeny N., Welt S., Lloyd K.O., Oettgen H.F., Old L.J., and Livingston P.O. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res. 52 (1992) 5663-5667
188. Longenecker B.M., Reddish M., Koganty R., and MacLean G.D. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann. N.Y. Acad. Sci. 690 (1993) 276-291
189. Miles D.W., Towlson K.E., Graham R., Reddish M., Longenecker B.M., Taylor-Papadimitriou J., and Rubens R.D. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer 74 (1996) 1292-1296
190. MacLean G.D., Miles D.W., Rubens R.D., Reddish M.A., and Longenecker B.M. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J. Immunother. Emphas.Tumor Immunol. 19 (1996) 309-316
191. Sandmaier B.M., Oparin D.V., Holmberg L.A., Reddish M.A., MacLean G.D., and Longenecker B.M. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J. Immunother. 22 (1999) 54-66
192. Holmberg L.A., Oparin D.V., Gooley T., Lilleby K., Bensinger W., Reddish M.A., MacLean G.D., Longenecker B.M., and Sandmaier B.M. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant. 25 (2000) 1233-1241
193. Holmberg L.A., Oparin D.V., Gooley T., and Sandmaier B.M. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope). Clin. Breast Cancer 3 Suppl 4 (2003) S144-S151
194. Ragupathi G., Koide F., Sathyan N., Kagan E., Spassova M., Bornmann W., Gregor P., Reis C.A., Clausen H., Danishefsky S.J., and Livingston P.O. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Cancer Immunol. Immunother. 52 (2003) 608-616
195. Kagan E., Ragupathi G., Yi S.S., Reis C.A., Gildersleeve J., Kahne D., Clausen H., Danishefsky S.J., and Livingston P.O. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol. Immunother. 54 (2005) 424-430
196. Ogata S., Chen A., and Itzkowitz S.H. Use of model cell lines to study the biosynthesis and biological role of cancer-associated sialosyl-Tn antigen. Cancer Res. 54 (1994) 4036-4044
197. Sorensen A.L., Reis C.A., Tarp M.A., Mandel U., Ramachandran K., Sankaranarayanan V., Schwientek T., Graham R., Taylor-Papadimitriou J., Hollingsworth M.A., Burchell J., and Clausen H. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 16 (2006) 96-107
198. Tarp M.A., Sorensen A.L., Mandel U., Paulsen H., Burchell J., Taylor-Papadimitriou J., and Clausen H. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 17 (2007) 197-209
199. Freire T., Lo-Man R., Piller F., Piller V., Leclerc C., and Bay S. Enzymatic large-scale synthesis of MUC6-Tn glycoconjugates for antitumor vaccination. Glycobiology 16 (2006) 390-401
200. M. Tenno, K. Ohtsubo, F.K. Hagen, D. Ditto, A. Zarbock, P. Schaerli, U.H. von Andrian, K. Ley, D. Le, L.A. Tabak, J.D. Marth, Initiation of Protein O-Glycosylation by Polypeptide GalNAcT-1 in Vascular Biology and Humoral Immunity, Mol. Cell. Biol. (2007) MCB.01204-07v1.